Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Passport Health Of Massachusetts Warns New Englanders, "Exploding Mosquito Population Can Be Deadly, Look For Repellents With At Least 30% DEET!"
Passport Health of Massachusetts, specialists in vaccinations against dread diseases faced by international travelers, is concerned that eastern New England"s wettest spring and early summer in decades can be more deadly than usual.

Insmed Announces Results Of IPLEX(TM) Phase II Trial In Myotonic Muscular Dystrophy
Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX(TM) (mecasermin rinfabate) in patients with myotonic muscular dystrophy ("MMD"). The randomized, double-blind, placebo-controlled Phase II trial conducted in 13 centers across the U.S. enrolled 69 patients with MMD, for a six-month period. As this was an exploratory trial, a primary endpoint was not pre-defined. The trial explored measures of endurance, using the six-minute walk test, muscle function and strength, cognitive function, gastrointestinal function, pain, quality of life, insulin sensitivity, lipid metabolism, and safety and tolerability of IPLEX(TM).
News of the day
New Data Confirm That Diovan(R) And Valsartan-Based Combinations Offer Patients Sustained, 24-hr BP-lowering Efficacy
Data presented at the 19th Scientific Meeting of the European Society of Hypertension (ESH) confirm that Diovan® (valsartan) and valsartan-based combinations deliver sustained, 24-hr blood pressure (BP)-lowering efficacy2-6.
Public Health

Results And Additional Analyses From Efficacy And Safety Study Of Corthera's Relaxin In Acute Heart Failure To Be Presented At Heart Failure Congress

Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera"s investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France. Marco Metra, M.D., professor of cardiology at the University of Brescia, Italy, and co-principal investigator of the Pre-RELAX-AHF study, will present the main results from the multicenter, international Pre-RELAX-AHF study at 8:30 a.m. CET on Sunday, May 31, at the Judges" Choice oral abstracts session. Dr. Metra will also present additional analyses of the Pre-RELAX-AHF study during a late-breaking clinical trials session at 11:15 a.m. CET on Monday, June 1. Five posters from the Pre-RELAX-AHF study will also be presented from 8:30 a.m. to 12:30 p.m. CET on Monday, June 1. About Relaxin Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure. About Corthera Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera"s lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. The company has worldwide rights to develop and commercialize relaxin. Corthera Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009